logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Advanced, metastatic esophageal cancer: pembrolizumab shows promise in phase 2 KEYNOTE-180

ESSC responded better than adenomas, both with manageable toxicity.